Terumo Interventional Systems has announced the full commercial availability in the United States of the Azur Peripheral HydroCoil 35 platinum coil embolization system. The Azur is a detachable hydrogel polymer embolic device with 0.035-inch coils and is compatible with 0.038-inch lumen catheters.
According to the company, the detachable Azur 35 is intended to reduce or block the rate of blood flow in vessels of the peripheral vasculature. It is designed for use in the interventional management of arteriovenous malformations, arteriovenous fistulas, aneurysms, and other lesions of the peripheral vasculature. The device’s design provides greater filling capacity, packing density, and mechanical occlusion particularly in the treatment of high-flow and challenging blood vessels, vascular malformations, and aneurysms.
Terumo stated that the hydrogel coating undergoes limited expansion within the first three minutes, and fully expands within 20 minutes. The Azur deploys rapidly and provides flexibility to position and observe the behavior of the coil in the vasculature before detachment. The device can be retracted and repositioned until it is securely placed, reducing the risk of nontarget embolization and coil migration. The microporous expandable hydrogel is biologically inert and provides scaffolding for natural tissue proliferation, the company added.
“In our experience, the Azur detachable 35 is an excellent embolization system that is very capable of treating higher capacity lesions with fewer coils, while effectively minimising risk of coil migration,” commented Craig Greben. “The larger coil size is highly deliverable and provides us with added confidence in treating high-blood flow areas or particularly challenging anatomies.”
